争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 1 条
2022
阿斯利康与中外制药就 Ultomiris 专利诉讼达成和解
和解
阿斯利康宣布与中外制药达成协议，解决所有与 Ultomiris 相关的专利争议。阿斯利康罕见病业务部门 Alexion 将于 2022 年第二季度一次性支付 7.75 亿美元。
来源摘录
Under the terms of the agreement, Alexion, AstraZeneca's Rare Disease group, will make a single payment of $775 million in the second quarter of 2022
AstraZeneca says agreement with Chugai Pharmaceutical resolving all patent disputes
Under the terms of the agreement, Alexion will make a single payment of $775m in the second quarter of 2022, for which a charge will be recognised through the non-core P&L in the first quarter of 2022.